Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 6/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | CRHBP | P24387 | 1/20 | 0.48 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.40 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6080172 | 0.98 | TDP1 (0.51) | TDP1MEN1KMT2AL3MBTL1MAPK1 | |
| SCHEMBL6080202 | 0.98 | TDP1 (0.51) | TDP1MEN1KMT2AL3MBTL1MAPK1 | |
| SCHEMBL7641684 | 0.98 | TDP1 (0.51) | TDP1MEN1KMT2AL3MBTL1MAPK1 | |
| SCHEMBL2224230 | 0.94 | TDP1 (0.54) | TDP1MEN1KMT2AL3MBTL1MAPK1 | |
| SCHEMBL1890789 | 0.90 | TDP1 (0.49) | TDP1MEN1KMT2AL3MBTL1MAPK1 | |
| SCHEMBL11655565 | 0.89 | TDP1 (0.56) | TDP1MEN1KMT2AL3MBTL1MAPK1 | |
| SCHEMBL7058682 | 0.89 | TDP1 (0.44) | TDP1MEN1KMT2AL3MBTL1MAPK1 | |
| SCHEMBL21073906 | 0.87 | TDP1 (0.55) | TDP1MEN1KMT2AL3MBTL1MAPK1 | |
| SCHEMBL6901399 | 0.87 | TDP1 (0.55) | TDP1MEN1KMT2AL3MBTL1MAPK1 | |
| SCHEMBL11500452 | 0.86 | TDP1 (0.51) | TDP1MEN1KMT2AL3MBTL1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070027198-A1 | Crystal of heterocyclic compound | OKADAI TAKESHI | 2007-02-01 | — | — | US | disclosed |
| CN-1238347-C | Heterocyclic derivatives | NIPPON SHINYAKU CO LTD (JP) | 2006-01-25 | — | — | CN | disclosed |
| CN-1430612-A | Hete rocyclic derivatives | NIPPON SHINYAKU CO LTD (JP) | 2003-07-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027198-A1 | Crystal of heterocyclic compound | GPR119, ACACA, HMGCR | TDP1 2767/4885MEN1 2057/4885KMT2A 590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.